# Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

> **NCT04842812** · PHASE1 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Liver Cancer
- Lung Cancer
- Breast Cancer
- Colo-rectal Cancer
- Brain Tumor
- Solid Tumor, Adult
- PD1
- CTLA4

## Interventions

- **BIOLOGICAL:** TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3

## Key facts

- **NCT ID:** NCT04842812
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2035-01-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842812, "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04842812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*